Latest Us Partnerships News

Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.

Ionic Rare Earths is pushing toward commercial magnet recycling in Belfast and the United States, but its FY2026 report flags a material uncertainty over its ability to continue as a going concern. The company reported a larger A$14.9 million loss and A$13.9 million in operating cash outflows, despite government support and new strategic partnerships.

Atomo Diagnostics lifted revenue 41% to AUD 5.33 million for FY26, cutting its loss by 29% to AUD 3.51 million, driven by HIV self-testing growth and a key US partnership. Leadership changes signal a strategic pivot as the company eyes global expansion.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Fortuna Metals has declared a maiden mineral resource at its Mkanda project in Malawi, ranking it among the top six rutile deposits worldwide, while locking in a strategic US investment of A$8.6 million from WNDR to boost market exposure.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

LTR Pharma has formalised its US commercialisation strategy by signing a definitive agreement with telehealth leader Shed, targeting at least 150,000 ROXUS units in the first year through digital men’s health platforms.

Bridge SaaS Limited has exited its non-core investment in Brightside Disability Support, recouping its initial outlay and sharpening its focus on AI-driven disability services and robotics innovation.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Pure Resources has completed a pivotal sampling program at Garnet Hill, securing over 100 kg of material to underpin its multi-stream US defence materials platform, targeting abrasive garnet, jumbo flake graphite, and rare earth recovery.

Pure Resources has launched an integrated Defence Materials Platform Strategy for its Garnet Hills Project, leveraging US government collaborations to diversify from commodity mining into advanced defence supply chains.